CryoCloud: Revolutionizing Cryo-EM Data Analysis
March 13, 2024, 1:20 pm
Utrecht-based biotech startup CryoCloud has secured €500,000 in funding to accelerate growth and streamline data analysis in the field of cryo-electron microscopy (cryo-EM). Led by Nina Capital, with contributions from Utrecht Health Seed Fund and ROM Utrecht Region, the funding will support CryoCloud's mission to make cryo-EM more accessible and efficient for scientists worldwide.
Founded in 2021 by Robert Englmeier, Ilja Gubins, and Boy Persoon, CryoCloud has developed a cloud-based data analysis platform that enables the fast and scalable determination of 3D protein structures crucial for drug discovery. By offering scalable cloud storage and user-friendly workflows, CryoCloud is breaking down barriers in cryo-EM research, making advanced tools more accessible to researchers at universities, biotechs, and cryo-EM facilities globally.
The investment from Nina Capital, a venture capital firm specializing in healthcare and technology, highlights the transformative potential of CryoCloud's digital solutions in the life sciences sector. Utrecht Health Seed Fund also sees the value in CryoCloud's platform, recognizing its ability to simplify and expand the use of cryo-EM in life sciences research.
With this funding, CryoCloud aims to further enhance its platform's capabilities, supporting scientists in their quest to unlock the mysteries of protein structures and accelerate drug discovery. By leveraging cloud technology and innovative data analysis methods, CryoCloud is revolutionizing the way cryo-EM data is analyzed, paving the way for groundbreaking discoveries in structural biology.
Founded in 2021 by Robert Englmeier, Ilja Gubins, and Boy Persoon, CryoCloud has developed a cloud-based data analysis platform that enables the fast and scalable determination of 3D protein structures crucial for drug discovery. By offering scalable cloud storage and user-friendly workflows, CryoCloud is breaking down barriers in cryo-EM research, making advanced tools more accessible to researchers at universities, biotechs, and cryo-EM facilities globally.
The investment from Nina Capital, a venture capital firm specializing in healthcare and technology, highlights the transformative potential of CryoCloud's digital solutions in the life sciences sector. Utrecht Health Seed Fund also sees the value in CryoCloud's platform, recognizing its ability to simplify and expand the use of cryo-EM in life sciences research.
With this funding, CryoCloud aims to further enhance its platform's capabilities, supporting scientists in their quest to unlock the mysteries of protein structures and accelerate drug discovery. By leveraging cloud technology and innovative data analysis methods, CryoCloud is revolutionizing the way cryo-EM data is analyzed, paving the way for groundbreaking discoveries in structural biology.